Edward Nash
Stock Analyst at Canaccord Genuity
(4.12)
# 411
Out of 4,786 analysts
77
Total ratings
46.27%
Success rate
15.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $1.22 | +637.70% | 2 | Feb 26, 2025 | |
| VRNA Verona Pharma | Maintains: Buy | $44 → $72 | $62.46 | +15.28% | 9 | Feb 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $22 → $45 | $17.76 | +153.45% | 9 | Feb 12, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Hold | $4 | $1.29 | +210.10% | 2 | Feb 10, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $78 → $130 | $102.88 | +26.36% | 6 | Jan 30, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $56 → $73 | $39.91 | +82.91% | 6 | Jan 28, 2025 | |
| APGE Apogee Therapeutics | Initiates: Buy | $89 | $36.85 | +141.55% | 1 | Nov 25, 2024 | |
| VTYX Ventyx Biosciences | Maintains: Buy | $15 → $14 | $1.13 | +1,138.50% | 6 | Aug 12, 2024 | |
| CRDL Cardiol Therapeutics | Maintains: Buy | $6 → $8 | $0.95 | +742.02% | 3 | May 23, 2024 | |
| IVA Inventiva | Maintains: Buy | $12 → $20 | $3.04 | +557.89% | 2 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $338 → $377 | $326.82 | +15.35% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $8 | $1.38 | +479.71% | 4 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $2.94 | +478.23% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.16 | -7.41% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $1.43 | +12,531.58% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $35.34 | +132.03% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $4.30 | +1,760.47% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $10.93 | +339.16% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $4.65 | +13,893.54% | 1 | Nov 8, 2017 |
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $1.22
Upside: +637.70%
Verona Pharma
Feb 12, 2025
Maintains: Buy
Price Target: $44 → $72
Current: $62.46
Upside: +15.28%
Travere Therapeutics
Feb 12, 2025
Maintains: Buy
Price Target: $22 → $45
Current: $17.76
Upside: +153.45%
Pliant Therapeutics
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.29
Upside: +210.10%
Corcept Therapeutics
Jan 30, 2025
Maintains: Buy
Price Target: $78 → $130
Current: $102.88
Upside: +26.36%
Akero Therapeutics
Jan 28, 2025
Maintains: Buy
Price Target: $56 → $73
Current: $39.91
Upside: +82.91%
Apogee Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $36.85
Upside: +141.55%
Ventyx Biosciences
Aug 12, 2024
Maintains: Buy
Price Target: $15 → $14
Current: $1.13
Upside: +1,138.50%
Cardiol Therapeutics
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $0.95
Upside: +742.02%
Inventiva
Apr 8, 2024
Maintains: Buy
Price Target: $12 → $20
Current: $3.04
Upside: +557.89%
Mar 15, 2024
Maintains: Buy
Price Target: $338 → $377
Current: $326.82
Upside: +15.35%
Jul 3, 2023
Assumes: Hold
Price Target: $8
Current: $1.38
Upside: +479.71%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $2.94
Upside: +478.23%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.16
Upside: -7.41%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $1.43
Upside: +12,531.58%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $35.34
Upside: +132.03%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $4.30
Upside: +1,760.47%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $10.93
Upside: +339.16%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $4.65
Upside: +13,893.54%